MapLight Therapeutics (MPLT) Return on Capital Employed (2025 - 2026)
MapLight Therapeutics (MPLT) posted Return on Capital Employed of 45.02% for Q4 2025.
MapLight Therapeutics (MPLT) Return on Capital Employed (2025 - 2026) Analysis & Trends
MapLight Therapeutics has reported Return on Capital Employed for 1 years, with the latest figure at 45.02% in Q4 2025.
- Quarterly Return on Capital Employed changed N/A year-over-year to 45.02% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 45.02% (changed N/A YoY) and the FY2025 annual result came in at 57.91%, changed N/A from the prior year.
- Return on Capital Employed held at 45.02% in Q4 2025 per MPLT's latest filing.
- Over five years, Return on Capital Employed peaked at 45.02% in Q4 2025 and troughed at 45.02% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | -51.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.67% |
| Dec 31, 2025 | -45.02% |